BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gabapentin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gabapentin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04860141-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gabapentin: Phase 4 readout est. (NCT04860141)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Efficacy of Preoperative Administ
 ration of Gabapentin in 3rd Molar Dental Extraction.\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gabapentin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04860141
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06379425-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Gabapentin: Phase 4 readout est. (NCT06379425)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Impact of Preoperative Opioid-fre
 e Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecolog
 ic Surgeries\nEstimated primary completion: 1 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gabapentin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06379425
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813026-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Gabapentin: Phase 4 readout est. (NCT07813026)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Abuse Potential of Gabapentin Tak
 en Orally Concomitantly With Oxycodone Hydrochloride in Healthy\, Non-Drug
 -Dependent\, Recreational Opioid Users\nEstimated primary completion: 31 J
 anuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gabapent
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7813026
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916116-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Gabapentin: Phase 2/3 readout est. (NCT07916116)
DESCRIPTION:Gabapentin\, phase 2/3.\nStudy: Oral Gabapentin Versus Intraven
 ous Neostigmine/Atropine Versus Combination of Both for Prevention of PDPH
 \nEstimated primary completion: 1 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gabapentin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07916116
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997016-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gabapentin: Phase 4 readout est. (NCT06997016)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Enhanced Recovery After Surgery (
 ERAS) in Live Donor Kidney Transplant Recipients\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gaba
 pentin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06997016
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859839-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gabapentin: Phase 4 readout est. (NCT07859839)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Gabapentin vs. Benzonatate vs. St
 andard of Care for Cough in ILD\nEstimated primary completion: 30 June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/gabapentin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07859839
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840183-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gabapentin: Phase 4 readout est. (NCT07840183)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Epidural Analgesia Versus Opioid-
 sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdomini
 s Release\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/gabapentin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07840183
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047040-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Gabapentin: Phase 2/3 readout est. (NCT07047040)
DESCRIPTION:Gabapentin\, phase 2/3.\nStudy: Analgesic Efficacy of Pre-opera
 tive Dose of Ketorolac and Gabapentin\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gabapenti
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 047040
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750639-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Gabapentin: Phase 4 readout est. (NCT07750639)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Reducing Opioid Use After Upper E
 xtremity Surgery: Testing Lower Prescriptions and Pill Quantity\nEstimated
  primary completion: 30 November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/gabapentin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07750639
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308717-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20271216
DTEND;VALUE=DATE:20271217
SUMMARY:Gabapentin: Phase 4 readout est. (NCT07308717)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Gabapentin And Breast Surgery Dec
 ision Architecture Randomization Trial (GABS-DART) Protocol\nEstimated pri
 mary completion: 16 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gabapentin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07308717
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03498261-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Gabapentin: Phase 1 readout est. (NCT03498261)
DESCRIPTION:Gabapentin\, phase 1.\nStudy: A Prospective Randomized Double B
 lind Trial to Assess the Effect of a Single Preoperative Dose of Gabapenti
 n on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gabapentin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03498261
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724252-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gabapentin: Phase 2/3 readout est. (NCT04724252)
DESCRIPTION:Gabapentin\, phase 2/3.\nStudy: Gabapentin to Reduce Opioid Use
  Postoperatively (GROUP) in Children\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gabapenti
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 724252
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941726-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gabapentin: Phase na readout est. (NCT07941726)
DESCRIPTION:Gabapentin\, phase na.\nStudy: Effect of GABAergic Treatments o
 n Cortical Plasticity and Motor Learning Capacity in the Subacute Phase Af
 ter Stroke\nEstimated primary completion: May 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gabapentin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07941726
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827159-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Gabapentin: Phase 3 readout est. (NCT05827159)
DESCRIPTION:Gabapentin\, phase 3.\nStudy: Emergency Department-Initiated Me
 dications for Alcohol Use Disorder\nEstimated primary completion: 1 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/gabapentin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0582715
 9
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992427-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Gabapentin: Phase 3 readout est. (NCT06992427)
DESCRIPTION:Gabapentin\, phase 3.\nStudy: High-dose Prophylactic Gabapentin
  (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During C
 oncurrent Chemoradiation for Head and Neck Cancer\nEstimated primary compl
 etion: 15 August 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gabapentin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06992427
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158476-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Gabapentin: Phase 4 readout est. (NCT07158476)
DESCRIPTION:Gabapentin\, phase 4.\nStudy: Efficacy of Methylprednisolone fo
 r Pain Control After ACL Repair\nEstimated primary completion: September 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gabapentin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07158476
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846020-4523@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20320115
DTEND;VALUE=DATE:20320116
SUMMARY:Gabapentin: Phase 1/2 readout est. (NCT07846020)
DESCRIPTION:Gabapentin\, phase 1/2.\nStudy: Mechanistic Evaluation of Polyp
 harmacy Effects for Pain\nEstimated primary completion: 15 January 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/gabapentin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07846020
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
